Back to Screener

Healthcare

TetraLogic Pharmaceuticals Corporation(TLOG)

Live Price

Offline

$0.00004

+0.00% today

1Y Change

-60.00%

Window

Jun 23, 2025 โ†’ Jun 12, 2026

Market Cap
โ€”
Revenue Growth
0.0%
EPS Growth
-34.7%
Dividend Yield
0.0%

Coverage: 247 bars ยท Jun 23, 2025 โ†’ Jun 12, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

TetraLogic Pharmaceuticals Corporation (TLOG) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 60.0% across the available one-year price window (Jun 23, 2025 โ†’ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -34.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -34.7%, free cash flow -6.3% with operating margin 0.0% and ROIC -74.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TLOG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2016 was reported on Nov 3, 2016, but the surprise data is still limited.

The operating picture looks softer than before

Revenue is at 0.0% and EPS is at -34.7%, with operating margin around 0.0%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2016
Nov 3, 2016
โ€”+0.0%+0.0%+0.0%
2016
Aug 11, 2016
โ€”+0.0%+0.0%+0.0%
2016
May 4, 2016
โ€”+0.0%+0.0%+0.0%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

TLOG

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

TLOG Max Drawdown

-96.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for TLOG and SPY.

Calendar-year return history is still loading or unavailable.
TetraLogic Pharmaceuticals Corporation logo

Company Overview

TetraLogic Pharmaceuticals Corporation

Other OTC

Malvern, PA, US
Visit tetralogicpharma.comCall IR610 889 9900

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Leadership
Yigong Shi
IPO Date
Dec 12, 2013
Employees
29
Street Address
343 Phoenixville Pike
Mailing
Malvern, PA, 19355
Region
Malvern, PA, US
Reporting Currency
USD
Investor Line
610 889 9900
Last Updated
May 5, 2026
CIK: 0001361248ISIN: US88165U1097CUSIP: 88165U109
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
โ€”
Price/Book
โ€”

Growth

Revenue
0.0%
EPS
-34.7%
Free Cash Flow
-6.3%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-408.6%
ROIC
-74.5%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
6.00

Earnings Reports

๐Ÿ“… Last reportedNov 3, 2016
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Nov 3, 16
-0.08
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Aug 11, 16
-0.22
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
May 4, 16
-0.45
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Mar 16, 16
-0.76
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Nov 4, 15
-0.34
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Aug 5, 15
-0.32
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
May 14, 15
-0.25
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Feb 26, 15
-0.38
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Nov 5, 14
โœ—
-0.42
Est -0.34
-23.5%
โ€”
Est โ€”
โ€”
โ€”
Aug 5, 14
โœ—
-0.42
Est -0.29
-44.8%
โ€”
Est โ€”
โ€”
โ€”
May 8, 14
โœ“
-0.25
Est -0.30
+16.7%
โ€”
Est โ€”
โ€”
โ€”
Dec 31, 13
-0.30
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 30, 13
-3.79
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jun 30, 13
-3.37
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Mar 31, 13
-3.12
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Dec 31, 12
-2.41
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks